Zevra Therapeutics Inc $ZVRA

Recent News (6)

• Zevra Therapeutics to Present at Upcoming Investor Conferences GlobeNewswire · 02 Sep 2026 BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people livi…
• Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium GlobeNewswire · 25 Aug 2026 Presentations from U.S. and German early access programs highlight sustained disease stabilization and a consistent safety profile across diverse NPC patient populations Presentations from U.S. and G…
• Zevra Therapeutics to Present at the Canaccord Genuity Annual Growth Conference GlobeNewswire · 04 Aug 2026 BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on bringing life-changing therapeutics to people livin…
• Zevra Therapeutics (ZVRA) Securities Investigation Notice - Levi & Korsinsky PR Newswire · 03 Aug 2026 Zevra investors who relied on public statements about arimoclomol's approval status faced losses after the July 24, 2026 negative opinion issued by the European Medicines Agency's Committee for Medici…
• Zevra Therapeutics Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Zevra Therapeutics (ZVRA) PR Newswire · 27 Jul 2026 Zvera investors saw shares fall roughly 24% after European regulators issued a negative CHMP opinion on arimoclomol. The investigation focuses on whether investors who suffered losses may have potenti…
• Zevra Therapeutics Provides Update on Regulatory Submission for Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union GlobeNewswire · 24 Jul 2026 Company plans to request re-examination following negative CHMP opinion for arimoclomol MAA